Kali Therapeutics Unveils Promising KT502 Data at EULAR 2026 Annual Congress
Groundbreaking Presentation of KT502 at EULAR 2026
Kali Therapeutics, a pioneering clinical-stage biotechnology firm, is making waves in the field of autoimmune disease treatment. With their innovative immune-resetting therapies, they recently announced that their latest candidate, KT502, will be presented in an oral discussion at the prestigious European Congress of Rheumatology (EULAR 2026). This congress is scheduled to take place from June 3-6, 2026, in London, UK.
The Significance of KT502
KT502 is an advanced CD19 x CD3 bispecific T-cell engager designed to effectively deplete B-cells both in peripheral circulation and within tissue. This novel approach is aimed at providing an essential
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.